Article metrics

Download PDFPDF

Original article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

 

Online download statistics by month:

Online download statistics by month: January 2019 to December 2021

AbstractFullPdf
Jan 2019436428157
Feb 2019274266145
Mar 2019216209103
Apr 201912812473
May 201911110163
Jun 2019948363
Jul 2019989544
Aug 2019757237
Sep 2019868448
Oct 201911311163
Nov 2019777246
Dec 2019676429
Jan 2020817343
Feb 2020494416
Mar 2020575030
Apr 2020604927
May 2020514536
Jun 2020655737
Jul 2020776838
Aug 2020654832
Sep 2020624827
Oct 2020484464
Nov 2020675530
Dec 2020403224
Jan 2021423822
Feb 2021484029
Mar 2021746543
Apr 2021655537
May 2021353224
Jun 2021534533
Jul 2021555233
Aug 2021747324
Sep 2021726423
Oct 2021908658
Nov 2021524738
Dec 2021635737
Total322029761676